| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2023-03-10 |
| タイトル |
|
|
タイトル |
Advanced gastrointestinal stromal tumor with intracerebral hemorrhage during sunitinib treatment\n |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
YAMAMURA, Masahiro
HIRAI, Toshihiro
OKAWAKI, Makoto
URAKAMI, Atsushi
TOMIYAMA, Yasuyuki
YAMAGUCHI, Yoshiyuki
|
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Clinical Oncology, Kawasaki Medical School |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Mitsugi General Hospital |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Clinical Oncology, Kawasaki Medical School |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of General Surgery |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Hepatology and Gastroenterology, Kawasaki Medical School・Department of Nutrition, The Faculty of Food Culture, Kurashiki Sakuyo University |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Clinical Oncology, Kawasaki Medical School |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Gastrointestinal stromal tumor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Sunitinib |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Angiogenesis inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Intracerebral hemorrhage |
| 抄録(英) |
|
|
言語 |
en |
|
値 |
Herein, a 70-year-old female was initially treated with sunitinib 50 mg/day to treat an imatinib-resistant gastrointestinal stromal tumor. After sunitinib initiation, nausea, hypertension, hepatic dysfunction, anorexia, fatigue, thrombocytopenia, epistaxis, and palmoplantar erythrodysesthesia syndrome developed; the dose was reduced to 25 mg/day.
Subsequently, adverse events improved, and from the fifth course onward, sunitinib 37.5 mg/day was continued. Approximately 11 months after initiating sunitinib therapy, the patient developed disturbance of consciousness, aphasia, and left hemiplegia. Computed tomography of the head revealed intracerebral hemorrhage, and the patient was hospitalized. No brain metastases, cerebral aneurysms, or cerebral arteriovenous malformations were observed. Sunitinib-induced hypertensive cerebral hemorrhage was suspected as the cause of intracerebral hemorrhage. Conservative treatments, such as antihypertensive drugs, were administered without surgical treatment. The symptoms and intracerebral hemorrhage gradually improved, and the patient was discharged from the hospital. Intracerebral hemorrhage with sunitinib is extremely rare, but has a high mortality rate. During sunitinib treatment, controlling blood pressure and thrombocytopenia is important to prevent bleeding. |
| 書誌情報 |
en : Kawasaki medical journal
巻 48,
p. 169-174,
発行日 2022
|
| 出版者 |
|
|
出版者 |
Kawasaki Medical Society |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
24343404 |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12029005 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.11482/KMJ-E202248169 |
| 記事種別(英) |
|
|
内容記述 |
Case Report |
|
言語 |
en |
| 関連サイト |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://igakkai.kms-igakkai.com/wp/wp-content/uploads/2022en/KMJ-E202248169.pdf |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
PDF (833.9 kB)
